

## Now Approved with Pass-through Status<sup>1</sup>



- Biosimilar to Avastin<sup>®</sup>
- Diluted solution storage of up to 12 hours vs 8 hours for Avastin
- Extended shelf life of up to 30 months vs 24 months for Avastin<sup>2</sup>
- Supported by the Amneal PATHways<sup>®</sup> patient support program
- CMS Outpatient Prospective Payment System (OPPS) pass-through indicator status of G

Unit of Sale	Unit of Sale Quantity	NDC	List (WAC) <sup>3</sup>
100 mg/4 mL (25 mg/mL)	Pack of 1 Single-Dose Vial	70121-1754-01	\$718.60
400 mg/16 mL (25 mg/mL)	Pack of 1 Single-Dose Vial	70121-1755-01	\$2,874.40

  

HCPCS Codes <sup>1</sup>	Descriptor
C9142	Injection, bevacizumab-maly, biosimilar, (alymysys), 10 mg (effective 10/1 - 12/31/22)
Q5126	Injection, bevacizumab-maly, biosimilar, (alymysys), 10 mg (effective 1/1/23)

Pack sizes and presentations available at launch may vary.

### IMPORTANT SAFETY INFORMATION

#### Indications and Usage

Alymsys (bevacizumab-maly) in the U.S. is a vascular endothelial growth factor inhibitor indicated for the treatment of:

- Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.
- Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
- First-Line non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel.
- Recurrent glioblastoma in adults.
- Metastatic renal cell carcinoma in combination with interferon alfa.
- Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
- Epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with paclitaxel

**Limitations of Use:** Alymsys is not indicated for adjuvant treatment of colon cancer.

1. Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Recommendations; Third Quarter, 2022 HCPCS Coding Cycle  
 2. Periodic Safety Update Report (PSUR) For Alymsys (Bevacizumab-maly), 22 April 2022  
 3. Wholesale Acquisition Cost (WAC) as of 10/3/2022

All trademarks are property of their respective owners. Images are for reference only; actual product may vary.



## Storage & Handling

Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton until time of use to protect from light. Do not freeze or shake the vial or carton.

Store diluted Alymsys solution at 2°C to 8°C (36°F to 46°F) for up to 12 hours.



**1-866-4AMNEAL**  
**(426-6325)**

Amneal is pleased to offer reimbursement access and patient support services through the PATHways program.

PATHways Patient Access Specialists are available to assist healthcare providers and patients with:

- Benefit investigation
- Prior authorization support
- Affordability options like co-pay savings
- Claims assistance

Call toll-free Monday through Friday, 8 AM to 8 PM ET.

### IMPORTANT SAFETY INFORMATION (continued)

#### Warnings and Precautions

Alymsys Important Safety Information includes warnings and precautions on severe and fatal hemorrhage; arterial and venous thromboembolic events; hypertension, hypertensive crisis, and hypertensive encephalopathy; renal injury, proteinuria, and nephrotic syndrome; posterior reversible encephalopathy syndrome; embryo-fetal toxicity; ovarian failure; congestive heart failure; gastrointestinal perforations and fistula; surgery and wound healing complications, and infusion-related reactions.

#### Adverse Reactions

Reported adverse drug reactions in patients include epistaxis, hemorrhage, hypertension, exfoliative dermatitis, proteinuria, back pain, headache, rhinitis, taste alteration, dry skin, and lacrimation disorder.

Visit [Alymsys.us](https://www.alymsys.us) for full Prescribing Information

**Alymsys**  
(bevacizumab-maly)



Order from your wholesaler or contact Amneal: Toll Free 866.525.7270 | [CustomerRelations@amneal.com](mailto:CustomerRelations@amneal.com)